Tag: GlobalData
Pricing and reimbursement delays critical headwind for biopharma industry innovation, finds...
The tougher price controls and policy shifts could erode revenues, slow launches, and weaken future drug development
UK–US pharma policies and US manufacturing shape global investment strategies, says...
Ministers have already cited multi-billion-pound commitments from Moderna, Bristol Myers Squibb, and BioNTech as evidence that tariff certainty and pricing reforms are strengthening confidence in the UK as an R&D and manufacturing base.
Biopharma enters 2026 with renewed and cautious optimism, says GlobalData
As per the report’s survey, 52% of pharmaceutical professionals felt optimistic or very optimistic about the industry’s growth in 2026, which is up by 10% compared to data gathered six months ago
Bipolar disorder market across 7MM set to grow at 5.3% CAGR...
GlobalData forecasts that the late-stage pipeline products could drive combined sales of approximately $2.8 billion by 2034 in the 7MM
CNS innovator oligonucleotide licensing value surges by 339% to $2.8 billion...
According to GlobalData’s Pharmaceutical Intelligence Center Deals Database, licensing agreements for innovator oligonucleotides targeting CNS indications secured a cumulative total deal value of $6.05 billion from 2021 to 2025 YTD
Cell and gene therapy market set to grow at 31.3% CAGR...
Significant advancements in treatments for dermatology disorders are anticipated, driven by innovations from both small to mid-size pharma and biotech companies
Biotech IPOs surge 68.4% YoY to $8.52 billion in 2024 amid...
According to GlobalData’s Pharmaceutical Intelligence Center Deals Database, completed IPOs that raised more than $100 million almost doubled, from $4.39 billion across 15 IPOs in 2023 to $7.88 billion across 24 IPOs in 2024
Coronary stents market in APAC to see sustained growth through 2034:...
The market is poised to grow at a compound annual growth rate (CAGR) of 3.2% in APAC between 2024 and 2034, outpacing the global CAGR of 1.2% over the same period
Pharma majors expand US manufacturing amid tariff pressures as BRICS boost...
GlobalData’s Emerging Market Outsourcing report reveals that this push for domestic production could lead to increased production costs and inflationary pressures on drug prices
FDA drug approvals drop 15.44% but smaller pharma leads innovation, reveals...
GlobalData’s Bio/Pharmaceutical Outsourcing report sheds light on the reliance of smaller pharma companies on contract development and manufacturing organizations (CDMOs) for production